Mankind Pharma Ltd
Mankind Pharma Ltd (MANKIND) last traded at ₹2,367, a market capitalisation of ₹97,756 crore, on a P/E of 45.8. Over the past 52 weeks the stock has ranged between ₹1,910 and ₹2,674. Mankind Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹4,031 crore and net profit of ₹574 crore. The next scheduled event is an EGM on 17 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Mankind Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Mankind Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹4,031 cr, up 12.9% from ₹3,570 cr a year earlier. Net profit was ₹574 cr, up 29.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3,061 | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | 4,031 |
| Expenses | 2,214 | 2,383 | 2,396 | 2,724 | 2,776 | 2,648 | 2,513 | 2,974 |
| Operating profit | 847 | 816 | 683 | 847 | 921 | 919 | 930 | 1,056 |
| OPM % | 28% | 26% | 22% | 24% | 25% | 26% | 27% | 26% |
| Other income | 109 | 87 | 249 | 83 | 94 | -31 | 94 | 49 |
| Interest | 7 | 221 | 191 | 171 | 170 | 157 | 142 | 110 |
| Depreciation | 100 | 187 | 231 | 219 | 222 | 223 | 223 | 226 |
| Profit before tax | 849 | 495 | 511 | 540 | 624 | 509 | 659 | 769 |
| Tax % | 22% | 22% | 17% | 18% | 17% | 19% | 15% | 25% |
| Net profit | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 |
| EPS (₹) | 16.31 | 9.22 | 10.20 | 10.62 | 12.39 | 9.90 | 13.43 | 13.75 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Mankind Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 6,214 | 7,782 | 8,749 | 10,260 | 12,207 | 14,278 | 14,738 |
| Operating profit | 1,649 | 1,991 | 1,902 | 2,517 | 3,026 | 3,625 | 3,827 |
| OPM % | 27% | 26% | 22% | 25% | 25% | 25% | 26% |
| Net profit | 1,293 | 1,453 | 1,310 | 1,942 | 2,011 | 1,938 | 2,068 |
| EPS (₹) | 31.59 | 35.78 | 32.00 | 47.75 | 48.26 | 46.34 | 49.47 |
TTM is the trailing twelve months to the most recent quarter.
Mankind Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- 18%
- 3 Years
- 18%
- TTM
- 14%
- 10 Years
- %
- 5 Years
- 11%
- 3 Years
- 17%
- TTM
- 13%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 10%
- 1 Year
- -7%
- 10 Years
- %
- 5 Years
- 17%
- 3 Years
- 16%
- Last Year
- 13%
Mankind Pharma Ltd shareholding pattern
Promoters held 72.63% at Jun 2026, broadly unchanged since Jun 2025. FIIs 9.45% and DIIs 15.39%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.87% | 72.71% | 72.70% | 72.67% | 72.67% | 72.66% | 72.66% | 72.63% |
| FIIs | 12.37% | 13.34% | 12.92% | 13.07% | 12.83% | 11.34% | 10.24% | 9.45% |
| DIIs | 9.91% | 11.05% | 11.47% | 11.50% | 11.91% | 13.26% | 14.46% | 15.39% |
| Public | 2.86% | 2.89% | 2.89% | 2.75% | 2.57% | 2.75% | 2.63% | 2.53% |
| No. of shareholders | 1,63,854 | 1,71,281 | 1,80,597 | 1,79,549 | 1,70,347 | 1,77,539 | 1,77,606 | 1,66,715 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Mankind Pharma Ltd events
The next scheduled event is an EGM on 17 Sept 2026.
- EGMPostal ballot for appointment of Mr. Anish Vafraj Bafna as a Non-Executive Independent Director
- OtherAppointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director
See the full results calendar for every Indian company reporting in the next 30 days.
Mankind Pharma Ltd corporate filings
- Intimation Regarding ESG RatingCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has submitted an intimation regarding its ESG rating to the stock…
Read the full analysis - Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has filed a press release dated August 20, 2026, under Regulation 30 of…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has published a newspaper advertisement regarding the notice of a Postal…
Read the full analysis - Please find attched postal ballot noticeAGM/EGMlow impact
Cruxal's analysis: Mankind Pharma Limited has issued a postal ballot notice to seek shareholder approval for…
Read the full analysis - Completion of realignment of Security Cover in respect of Non-Convertible Debentures.Company Updatelow impact
Cruxal's analysis: Mankind Pharma has finalized the realignment of security cover for its Non-Convertible…
Read the full analysis - Announcement under Regulation 30 (LODR)-Updates on AcquisitionCompany Updatelow impact
Cruxal's analysis: Mankind Pharma Limited has officially completed the incorporation of its wholly owned…
Read the full analysis - Board Meeting Outcome for For Appointment Of An Additional Director Designated As Non-Executive Independent DirectorOtherslow impact
Cruxal's analysis: Mankind Pharma Limited has announced the appointment of Mr. Anish Vanraj Bafna as an…
Read the full analysis - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationCompany Updatelow impact
Cruxal's analysis: Mankind Pharma has issued an intimation regarding its participation in scheduled investor…
Read the full analysis - Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAGM/EGMlow impact
Cruxal's analysis: Mankind Pharma Limited has successfully concluded its 35th Annual General Meeting held on…
Read the full analysis - Shareholder Meeting / Postal Ballot-Outcome of AGMAGM/EGMlow impact
Cruxal's analysis: Mankind Pharma Limited announced the conclusion of its 35th Annual General Meeting (AGM)…
Read the full analysis - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptCompany Updatehigh impact
Cruxal's analysis: Mankind Pharma Limited delivered robust financial performance in Q1 FY27, with overall…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Mankind Pharma Ltd
Cruxal reads every Mankind Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.